Cargando…
Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
OBJECTIVE: To assess outcomes in treatment-naive eyes with neovascular age-related macular degeneration (nAMD) and good baseline visual acuity (VA) treated using a treat-and-extend (T&E) regimen with intravitreal aflibercept, ranibizumab, or bevacizumab. DESIGN: Single center, retrospective, obs...
Autores principales: | Khanani, Arshad M, Gahn, Greggory M, Koci, Micaela M, Dang, Jonathan M, Brown, Sandra M, Hill, Lauren F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387604/ https://www.ncbi.nlm.nih.gov/pubmed/30858684 http://dx.doi.org/10.2147/OPTH.S191170 |
Ejemplares similares
-
New Therapies of Neovascular AMD beyond Anti-VEGF Injections
por: Gahn, Greggory M., et al.
Publicado: (2018) -
Clinical experience with fixed bimonthly aflibercept dosing in treatment-experienced patients with neovascular age-related macular degeneration
por: Khanani, Arshad M
Publicado: (2015) -
Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020
por: Samanta, Anindya, et al.
Publicado: (2020) -
OPTIMAL MANAGEMENT OF PIGMENT EPITHELIAL DETACHMENTS IN EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
por: Khanani, Arshad M., et al.
Publicado: (2018) -
Baseline characteristics and progression of neovascular age-related macular degeneration in patients receiving over 60 intravitreal injections of anti-vascular endothelial growth factor
por: Prahs, Philipp, et al.
Publicado: (2023)